lidERA Breast Cancer is a phase III, randomized, open-label, multicentre study evaluating the efficacy and safety of adjuvant giredestrant versus standard-of-care endocrine therapy in patients with ...

Patients with triple-negative breast cancer who cannot receive immunotherapy now have a new first-line treatment option after ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy ...

FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...

Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast ...

Adding targeted therapy Kisqali (ribociclib) to the standard treatment plan can significantly reduce the risk of cancer coming back for patients with hormone receptor-positive (HR+) breast cancer.

At the American Society of Clinical Oncology (ASCO) meeting, results from the OPTIMA trial suggested that genomic testing may help identify additional patients with hormone ...

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.” Dr. Sara Nunnery, a breast medical oncologist and the ...

HER2-positive cancers overexpress the human epidermal growth factor receptor 2. When expressed at abnormally high levels, HER2 leads to uncontrolled cell growth and a more aggressive behavior than ...

Phase 3 persevERA missed the primary endpoint, with no statistically significant improvement in investigator-assessed PFS for giredestrant plus palbociclib versus letrozole plus palbociclib in the ITT ...